Scientific Presentation with Prof. John Bartlett reviewing the current data on how the success of ADCs raises questions about patient selection and identification of responders.
Highly effective antibody-drug conjugates (ADCs) are impacting clinical practice
The level of target expression for successful ADC targeting remains unknown
Present assays are predicated on measurement of biological pathway effects (esp for HER2) and may underestimate responsive populations
Precise mechanisms of action and resistance unknown
Further work required to match patients to optimal ADC approaches